2. Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: A review for general practitioners in oncology. Curr Oncol. 2022;29: 1828-39. doi: 10.3390/curroncol29030150
3. Jasper K, Stiles B, McDonald F, Palma DA. Practical management of oligometastatic non–small-cell lung cancer. J Clin Oncol. 2022;40: 635-41. doi: 10.1200/jco.21.01719
4. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28: 2181-90. doi: 10.1200/jco.2009.26.2543
5. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387: 1540-50. doi: 10.1016/s0140-6736(15)01281-7
6. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393: 1819-30. doi: 10.1016/s0140-6736(18)32409-7
7. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN guidelines insights: non–small cell lung cancer, version 4.2016. J Natl Compr Canc Netw. 2016;14: 255-64. doi: 10.6004/jnccn.2016.0031
8. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. J Clin Oncol. 2022;40: 1301-11. doi: 10.1200/jco.21.01308
9. Wu J, Ni T, Deng R, Li Y, Zhong Q, Tang F, et al. Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis. Front Immunol. 2023;14: 1065510. doi: 10.3389/fimmu.2023.1065510
10. Zhang Y, Tian Y, Zheng L, Sun X, Zhao Z, Zheng Y, et al. Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies. Front Pharmacol. 2023;14: 1103927. doi: 10.3389/fphar.2023.1103927
11. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377: 1919-29. doi: 10.1056/NEJMoa1709937
12. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN guidelines® insights: Non-small cell lung cancer, version 2.2023. J Natl Compr Canc Netw. 2023;21: 340-50. doi: 10.6004/jnccn.2023.0020
13. Xuan L, Bai C, Ju Z, Luo J, Guan H, Zhou PK, et al. Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy. Cytokine Growth Factor Rev. 2023. doi: 10.1016/j.cytogfr.2023.11.003
14. Brandmaier A, Formenti SC. The impact of radiation therapy on innate and adaptive tumor immunity. Semin Radiat Oncol. 2020;30: 139-44. doi: 10.1016/j.semradonc.2019.12.005
15. Procureur A, Simonaggio A, Bibault JE, Oudard S, Vano YA. Enhance the immune checkpoint inhibitors efficacy with radiotherapy induced immunogenic cell death: A comprehensive review and latest developments. Cancers (Basel). 2021;13. doi: 10.3390/cancers13040678
16. Davar D, Zarour HM. Immunological targets for immunotherapy: inhibitory T cell receptors. Methods Mol Biol. 2020;2055: 23-60. doi: 10.1007/978-1-4939-9773-2_2
17. Du SS, Chen GW, Yang P, Chen YX, Hu Y, Zhao QQ, et al. Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation. Int J Radiat Oncol Biol Phys. 2022;112: 1243-55. doi: 10.1016/j.ijrobp.2021.12.162
18. Galluzzi L, Aryankalayil MJ, Coleman CN, Formenti SC. Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023;20: 543-57. doi: 10.1038/s41571-023-00782-x
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45: 228-47. doi: 10.1016/j.ejca.2008.10.026
20. Abe T, Iino M, Saito S, Aoshika T, Ryuno Y, Ohta T, et al. Comparison of the efficacy and toxicity of concurrent chemoradiotherapy and durvalumab and concurrent chemoradiotherapy alone for locally advanced non-small cell lung cancer with N3 lymph node metastasis. Anticancer Res. 2023;43: 675-82. doi: 10.21873/anticanres.16205
21. Akamatsu H, Murakami H, Harada H, Shimizu J, Hayashi H, Daga H, et al. Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced NSCLC with EGFR mutation; West Japan Oncology Group 6911L. J Thorac Oncol. 2021;16: 1745-52. doi: 10.1016/j.jtho.2021.05.019
22. Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, et al. A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study. J Thorac Oncol. 2022;17: 130-40. doi: 10.1016/j.jtho.2021.08.019
23. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, et al. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022;174: 112-7. doi: 10.1016/j.lungcan.2022.10.006
24. Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020;8. doi: 10.1136/jitc-2020-001001
25. Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, et al. Durvalumab plus concurrent radiotherapy for treatment of locally advanced non-small cell lung cancer: The DOLPHIN phase 2 nonrandomized controlled trial. JAMA Oncol. 2023;9: 1505-13. doi: 10.1001/jamaoncol.2023.3309
26. Jabbour SK, Berman AT, Decker RH, Lin Y, Feigenberg SJ, Gettinger SN, et al. Phase 1 trial of Pembrolizumab administered concurrently with Chemoradiotherapy for locally advanced non–small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 2020;6: 848-55. doi: 10.1001/jamaoncol.2019.6731
27. Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, et al. Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIA-B NSCLC: results from the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). J Thorac Oncol. 2021;16: 278-88. doi: 10.1016/j.jtho.2020.10.129
28. Tang S, Cong X, Zheng D, Chen C, Liu Z, Gao J, et al. Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study. Front Oncol. 2023;13: 1129989. doi: 10.3389/fonc.2023.1129989
29. Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer: The phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. 2021;7: 1-9. doi: 10.1001/jamaoncol.2021.2301
30. Denault MH, Feng J, Kuang S, Shokoohi A, Leung B, Liu M, et al. Beyond PACIFIC: Real-world outcomes of adjuvant durvalumab according to treatment received and PD-L1 expression. Curr Oncol. 2023;30: 7499-507. doi: 10.3390/curroncol30080543
31. Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D'Angelo E, et al. A real-world, multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable stage III non-small cell lung cancer. Front Oncol. 2021;11: 744956. doi: 10.3389/fonc.2021.744956
32. Desilets A, Blanc-Durand F, Lau S, Hakozaki T, Kitadai R, Malo J, et al. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. Eur J Cancer. 2021;142: 83-91. doi: 10.1016/j.ejca.2020.10.008
33. Conibear J. Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer. Br J Cancer. 2020;123: 10-7. doi: 10.1038/s41416-020-01070-6
34. Guan S, Ren K, Zhang X, Yan M, Li X, Zhao L. Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study. Radiat Oncol. 2023;18: 122. doi: 10.1186/s13014-023-02305-5
35. Kashihara T, Nakayama Y, Okuma K, Takahashi A, Kaneda T, Katagiri M, et al. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer. Radiother Oncol. 2023;180: 109454. doi: 10.1016/j.radonc.2022.109454
36. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378: 2078-92. doi: 10.1056/NEJMoa1801005
37. Wu L, Zhang Z, Bai M, Yan Y, Yu J, Xu Y. Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations. Cell Commun Signal. 2023;21: 119. doi: 10.1186/s12964-023-01139-8
38. Avrillon V, Daniel C, Boisselier P, et al. Nationwide real-life safety and treatment exposure data on durvalumab after concurrent chemoradiotherapy in unresectable stage III, locally advanced, non-small cell lung cancer: analysis of patients enrolled in the French Early Access Program[J]. Lung, 2022, 200(1): 95-105.
39. Preti B T B, Sanatani M S, Breadner D, et al. Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer[J]. Current Oncology, 2023, 30(8): 7713-7721.
40. Ellison C, Martens M, Argote J A, et al. High-grade pneumonitis events in unresectable, locally advanced non-small cell lung cancer patients treated with definitive chemoradiation followed by adjuvant durvalumab[J]. JTO Clinical and Research Reports, 2023: 100537.
41. Guberina N, Wirsdörfer F, Stuschke M, et al. Combined radiation-and immune checkpoint-inhibitor-induced pneumonitis–The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging[J]. Neoplasia, 2023, 39: 100892.
42. Chen Y, Gao M, Huang Z, et al. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges[J]. Journal of hematology & oncology, 2020, 13: 1-17
43. Zayed S, Louie A V, Breadner D A, et al. Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions[J]. Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231183668.
44. Weichselbaum R R, Liang H, Deng L, et al. Radiotherapy and immunotherapy: a beneficial liaison?[J]. Nature reviews Clinical oncology, 2017, 14(6): 365-379.
45. Janopaul-Naylor J R, Shen Y, Qian D C, et al. The abscopal effect: a review of pre-clinical and clinical advances[J]. International journal of molecular sciences, 2021, 22(20): 11061
46. Dovedi S J, Adlard A L, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J]. Cancer research, 2014, 74(19): 5458-5468.
47. Twyman-Saint Victor C, Rech A J, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature, 2015, 520(7547): 373-377